Résztvevőt keres itt: Egyesült Államok1/2. fázis
A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
A legfontosabb adatok
- Ki végzi
- Coherus Oncology, Inc.
- Hol
- Seattle (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1/2. fázis
- Résztvevők
- 12 fő, tervezett
- Kezdés
- 2026. nov.
- Várható befejezés
- 2028. aug.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Tagmokitug
- Pasritamig
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment; mCRPC:
- Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is not permitted
- Measurable Castration-resistant Prostate Cancer (mCRPC) as defined by PCWG3 criteria. Participant must have mCRPC that is metastatic either to bone, lymph node (LN), or both without clear evidence of either measurable or nonmeasurable metastasis to visceral organs at the time of screening scan
- Participants must have been previously treated with at least 1 prior androgen-receptor pathway inhibitor (ARPI) (ie, abiraterone acetate, enzalutamide, apalutamide, darolutamide)
- Participants must have received at least one prior taxane therapy unless the participant is ineligible or refused. Participants must not have received other prior cytotoxic chemotherapy (ie, cisplatin, carboplatin, etoposide)
- Prior orchiectomy or medical castration. Participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog with testosterone ≤50 nanogram per deciliter (ng/dL) prior to the first dose of study drug and must continue this therapy throughout the treatment phase
Ki nem vehet részt
- Prior exposure to anti-CCR8 antibody agents
- Prior allogeneic hematological stem cell transplantation or organ transplantation; mCRPC:
- Any known prior history of brain metastases of prostate cancer (PCa)
- Treatment with antineoplastic therapy (including but not limited to cytotoxic chemotherapy, biologic agents, and investigational agents) other than ADT or ARPI within 28 days or <5× the elimination half-life (t½), whichever is earlier, before Day 1
- Prior exposure to a T cell engager or human kallikrein 2 (KLK2) targeted therapy
- Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study; Additional protocol-defined inclusion and exclusion criteria apply
- History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Fred Hutchinson Cancer CenterSeattle, Egyesült ÁllamokContact: Clinical Operations TeamRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.
A vizsgálat csoportja
- mCRPC: Tagmokitug + PasritamigA vizsgált kezelés
Kezelés: Tagmokitug és Pasritamig
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
- A regiszteradat frissítve
- 2026. november 18.